Cytokinetics (CYTK)
NASDAQ:CYTK
Want to see CYTK full AI Analyst Report?
Total Valuation
Cytokinetics has a market cap or net worth of $9.80B. The enterprise value is $10.71B.
Market Cap$9.80B
Enterprise Value$10.71B
Share Statistics
Cytokinetics has 124,432,560 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding124,432,560
Owned by Insiders0.81%
Owned by Institutions10.21%
Financial Efficiency
Cytokinetics’s return on equity (ROE) is 1.19 and return on invested capital (ROIC) is -47.74%.
Return on Equity (ROE)1.19
Return on Assets (ROA)-0.55
Return on Invested Capital (ROIC)-47.74%
Return on Capital Employed (ROCE)-0.50
Revenue Per Employee176.79K
Profits Per Employee-1.58M
Employee Count498
Asset Turnover0.06
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Cytokinetics is ―. Cytokinetics’s PEG ratio is -0.40.
PE Ratio―
PS Ratio86.62
PB Ratio-11.56
Price to Fair Value-11.56
Price to FCF-14.26
Price to Operating Cash Flow-18.54
PEG Ratio-0.40
Income Statement
In the last 12 months, Cytokinetics had revenue of 88.04M and earned -784.96M in profits. Earnings per share was -6.54.
Revenue88.04M
Gross Profit77.91M
Operating Income-612.26M
Pretax Income-784.96M
Net Income-784.96M
EBITDA-775.27M
Earnings Per Share (EPS)-6.54
Cash Flow
In the last 12 months, operating cash flow was -523.85M and capital expenditures -25.07M, giving a free cash flow of -548.92M billion.
Operating Cash Flow-523.85M
Free Cash Flow-548.92M
Free Cash Flow per Share-4.41
Dividends & Yields
Cytokinetics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.92
52-Week Price Change158.39%
50-Day Moving Average66.80
200-Day Moving Average60.12
Relative Strength Index (RSI)65.38
Average Volume (3m)2.88M
Important Dates
Cytokinetics upcoming earnings date is Jul 30, 2026, After Close (Confirmed).
Last Earnings DateMay 5, 2026
Next Earnings DateJul 30, 2026
Ex-Dividend Date―
Financial Position
Cytokinetics as a current ratio of 4.53, with Debt / Equity ratio of -126.00%
Current Ratio4.53
Quick Ratio4.53
Debt to Market Cap0.15
Net Debt to EBITDA-0.52
Interest Coverage Ratio-5.89
Taxes
In the past 12 months, Cytokinetics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Cytokinetics EV to EBITDA ratio is -10.36, with an EV/FCF ratio of -15.01.
EV to Sales91.19
EV to EBITDA-10.36
EV to Free Cash Flow-15.01
EV to Operating Cash Flow-15.74
Balance Sheet
Cytokinetics has $818.55M in cash and marketable securities with $1.04B in debt, giving a net cash position of -$222.96M billion.
Cash & Marketable Securities$818.55M
Total Debt$1.04B
Net Cash-$222.96M
Net Cash Per Share-$1.79
Tangible Book Value Per Share-$5.50
Margins
Gross margin is 90.34%, with operating margin of -695.44%, and net profit margin of -891.60%.
Gross Margin90.34%
Operating Margin-695.44%
Pretax Margin-891.60%
Net Profit Margin-891.60%
EBITDA Margin-880.60%
EBIT Margin-891.60%
Analyst Forecast
The average price target for Cytokinetics is $98.58, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$98.58
Price Target Upside47.77% Upside
Analyst ConsensusStrong Buy
Analyst Count19
Revenue Growth Forecast450.60%
EPS Growth Forecast-28.90%